Clinical trials: 5-FU, completed
Metastatic Pancreatic Adenocarcinoma
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic…
- Trial name
- NCT01896869
- Testing
- Ipilimumab, Vaccine, FOLFIRINOX
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for…
- Trial name
- NCT03929666
- Testing
- ZW25 (Zanidatamab), Capecitabine, Cisplatin
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 74 people
- Sponsor
- Jazz Pharmaceuticals
Colorectal Neoplasms
A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
This open-label, prospective, single-arm, multicenter study will evaluate the relationship of the markers of inflammation and progression-free survival (PFS) in participants with previously untreated metastatic colorectal cancer.
- Trial name
- ASCENT (NCT01588990)
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- 17 sites in Australia
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00015886
- Testing
- docetaxel, fluorouracil
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer
Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer
The purpose of this study is to evaluate if giving bevacizumab prior to chemotherapy compared to giving bevacizumab at the same time as chemotherapy improves patient overall response to treatment.
- Trial name
- OBELICS (NCT01718873)
- Testing
- Bevacizumab, Oxaliplatin, levo-folinic acid
- Where
- Italy
- Volunteers
- 230 people
- Sponsor
- National Cancer Institute, Naples
Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor
RATIONALE: Drugs used in chemotherapy, such as docetaxel, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00711243
- Testing
- docetaxel, fluorouracil, oxaliplatin
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Northwestern University
Larynx Cancer, Hypopharynx Cancer
Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma
The purpose of the study is to compare two regimen of chemotherapy used as first treatment for patients with larynx or hypopharynx tumors that would be treated with total laryngectomy.
- Trial name
- NCT00169182
- Testing
- DOCETAXEL, Cisplatin, 5-Fluoro-3-Pyridinecarboxylic Acid
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Colorectal Cancer
Window of Opportunity Study in Colorectal Cancer
This is a window of opportunity translational study investigating the use of pre-operative pembrolizumab and chemotherapy or chemoradiotherapy in non-metastatic colorectal cancer.
- Trial name
- NCT03984578
- Testing
- CAPEOX, Pembrolizumab, Capecitabine/ 5-FU
- Where
- 3 sites in Singapore
- Volunteers
- 33 people
- Sponsor
- National Cancer Centre, Singapore
Biliary Tract Cancer (BTC), Colorectal Cancer (CRC)
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
- Conditions
- Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer, Gastroesophageal Cancer (GC)
- Trial name
- NCT03314935
- Testing
- INCB001158, Oxaliplatin, Leucovorin
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 149 people
- Sponsor
- Incyte Corporation
Colorectal Cancer
An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)
This prospective, multicenter, observational study will investigate the effectiveness and safety of bevacizumab in routine clinical practice in participants with metastatic CRC.
- Trial name
- AVACONT (NCT02305615)
- Testing
- Bevacizumab, Chemotherapy
- Where
- 22 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Cancer
Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002476
- Testing
- bleomycin sulfate, fluorouracil, leucovorin calcium
- Where
- 7 sites in India, United Kingdom
- Sponsor
- Cancer Research UK
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
Patients with locally advanced or metastatic gastric carcinoma or carcinoma of the esophagogastric junction without prior palliative therapy will be treated with 8 cycles of the FLOT scheme (up to 12 cycles if the response is…
- Trial name
- FLOT3 (NCT00849615)
- Testing
- Docetaxel, 5-Fluorouracil, Oxaliplatin
- Where
- Germany
- Volunteers
- 252 people
- Sponsor
- Krankenhaus Nordwest
Colorectal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268333
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- 9 sites in France
- Volunteers
- 39 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
PURPOSE: This randomized phase III trial is studying cetuximab and/or bevacizumab when given together with combination chemotherapy to compare how well they work in treating patients with metastatic colorectal cancer.
- Trial name
- NCT00265850
- Testing
- bevacizumab, cetuximab, FOLFOX or
- Where
- 683 sites in United States, Canada
- Volunteers
- 2,334 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
- Trial name
- HORIZON III (NCT00384176)
- Testing
- Cediranib, Bevacizumab, 5-fluorouracil ( in FOLFOX)
- Where
- 280 sites in United States, Australia and 26 more
- Volunteers
- 1,814 people
- Sponsor
- AstraZeneca
Gastric Cancer
Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE)
Post-operative radio-chemotherapy decrease the recurrence risk of gastric cancer(N Engl J Med 2001). However the chemotherapy regimen (5 fluorouracil IV bolus) used was toxic and suboptimal.
- Trial name
- TRACE (NCT00512304)
- Testing
- association chemotherapy and radiochemotherapy
- Where
- France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Rouen
Nasopharyngeal Carcinoma
Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma
The aim of the study is to assess if gemcitabine in combination with carboplatin as 1st line chemotherapy in patients with metastatic or recurrent nasopharyngeal carcinoma has reasonable efficacy and a favourable toxicity profile…
- Trial name
- NCT00697905
- Testing
- Gemcitabine, Carboplatin, Cisplatin
- Where
- 11 sites in Malaysia
- Volunteers
- 18 people
- Sponsor
- Ministry of Health, Malaysia
Gastric Cancer, Metastases
Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer
To assess the optimal sequence of the palliative chemotherapy regimen (DP --> FOLFIRI vs FOLFIRI --> DP) in metastatic gastric cancer patients.
- Trial name
- NCT00313872
- Testing
- DP, FOLFIRI
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Resectable Pancreatic Cancer
Borderline Pancreas Study: FOLFIRINOX +SBRT
Primary Objective: To determine the rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy. Secondary Objective(s): 1.
- Trial name
- GCC 1324 (NCT01992705)
- Testing
- Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Maryland, Baltimore
Metastatic Colorectal Cancer
Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients
Aim of the present study is to investigate whether baseline or early post-treatment (one month after treatment commencement) frequency of peripheral T regulatory lymphocytes (Tregs OR CD4+/CD25high/FOXP3+ T cells), known to…
- Trial name
- NCT01533740
- Testing
- fluorouracil/irinotecan/levo-folinic acid/bevacizumab
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- University of Rome Tor Vergata
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.